Identification of key genes unique to the luminal a and basal-like breast cancer subtypes via bioinformatic analysis

Jia, Rong; Li, Zhongxian; Liang, Wei; Ji, Yucheng; Weng, Yujie; Li, Ying; Ning, Pengfei

doi:10.1186/s12957-020-02042-z

Cited by 23 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNAs have a significant effect on the early diagnosis and prognostic evaluation of BC and on reversing the drug resistance of cancers [ 14 ]. All kinds of miRNAs have abnormal expression in BC [ 15 , 16 ], and these maladjusted miRNAs play an antitumour or carcinogenic role in the disease and are involved in its pathological process [ 17 , 18 ]. There is abnormal expression of miR-92b-3p in colorectal cancer [ 19 , 20 ] and oesophageal squamous cell carcinoma [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Expression levels and clinical values of miR-92b-3p in breast cancer

Miao

Wang

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

Background miR-92b is a carcinogenic miRNA that has great potential as a biomarker for disease prognosis, diagnosis, and treatment in the clinic. It is of great significance to analyse the relationship between miR-92b and the clinicopathological characteristics of cancer patients. This paper aimed to investigate the expression levels and clinical values of miR-92b-3p in breast cancer (BC). Methods Altogether, 112 female BC patients who were treated in our hospital were included as a study group, and 108 healthy women who came to our hospital for physical examinations were included as a control group. miR-92b-3p expression in the serum of subjects in both groups was detected by fluorescence quantitative PCR (RT-PCR) to analyse the correlation of this miRNA with the patients’ pathological features and prognoses. The diagnostic value of miR-92b-3p expression for BC was analysed by plotting a receiver operating characteristic (ROC) curve. Results miR-92b-3p expression was remarkably higher in the study group (P < 0.05), and its area under the curve (AUC) for detecting BC was 0.88. The expression was correlated with the tumour size, degree of differentiation, TNM staging, and lymphatic metastasis (P < 0.05). miR-92b-3p was significantly positively correlated with the TNM staging (r = 0.40, P < 0.05), was significantly negatively correlated with the degree of differentiation of the breast cancer cells (r = − 0.35, P < 0.05), and was significantly positively correlated with the expression of carbohydrate antigen 125 (CA125) (r = 0.39, P < 0.05). The overall survival rate (OSR) of the 99 patients who had follow-up was 73.74%. The survival status was remarkably better in the low expression group (P < 0.05). miR-92b-3p expression was remarkably higher in the death group (P < 0.05). The AUC of miR-92b-3p alone in the death and survival groups was 0.76. Conclusion miR-92b-3p expression obviously rises in the serum of BC patients and is closely related to the clinical staging, degree of differentiation, and CA125 in BC, so the detection of this miRNA is of great significance to the diagnosis and prognostic evaluation of BC. This miRNA can be used as a potential biomarker for the diagnosis and prognosis of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression levels and clinical values of miR-92b-3p in breast cancer

Miao

Wang

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Contrary to luminal A BRCA subtype, basal-like BRCA subtypes are associated with a poor prognosis [ 32 ]. Currently, numerous studies are investigating immune therapies for BRCA, especially basal-like subtypes, though only a minority of patients still appear to respond to this form of therapy.…”

Section: Discussionmentioning

confidence: 99%

Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer

Xiao

Yue

Tan

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

A common cancer in females, breast cancer (BRCA) mortality has been recently reduced; however, the prognosis of BRCA patients remains poor. This study attempted to develop prognostic immune-related long noncoding RNAs (lncRNAs) for BRCA and identify the effects of these lncRNAs on the tumor microenvironment (TME). Gene expression data from The Cancer Genome Atlas (TCGA) database were collected in order to select differentially expressed lncRNAs. Immune-related lncRNAs were downloaded from the ImmLnc database, where 316 immune-related lncRNAs were identified, 12 of which were found to be significantly related to the prognosis of BRCA patients. Multivariate cox regression analysis was then applied to construct prognostic immune-related lncRNAs as the risk model, including C6orf99, LINC00987, SIAH2-AS1, LINC01010, and ELOVL2-AS1. High-risk and low-risk groups were distinguished according to the median of immune-related risk scores. Accordingly, the overall survival (OS) in the high-risk group was observed to be shorter than that in the low-risk group. qRT-PCR analysis demonstrated that lncRNA expression levels in BRCA cell lines were in basic agreement with predictions except for LINC00987. By validating numerous clinical samples, lncRNA C6orf99 was shown to be highly expressed in the advanced stage, while LINC01010 and SIAH2-AS1 decreased in the advanced T-stage and M-stage. Moreover, the expression of LINC0098 was found to be significantly decreased among the groups (>50 years old). Gene set enrichment analysis (GSEA) was applied to analyze the cancer hallmarks and immunological characteristics of the high-risk and low-risk groups. Importantly, the TIMER database demonstrated that this immune-related lncRNA risk model for breast cancer is related to the infiltration of immune cells. In conclusion, the results indicated that five immune-related lncRNAs could be used as a prognostic model and may even accelerate immunotherapy for BRCA patients.

show abstract

“… 25 Additionally, NMUR1 has been identified as a prognostic biomarker of oropharyngeal cancer 26 and breast cancer patients. 27 The proteins encoded by TIMP1 are natural inhibitors of matrix metalloproteinases (MMPs), which are important regulators of the extracellular environment. TIMP1 in serum could identify colon cancer patients with a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of a Novel Inflammatory Response-Related Gene Signature for the Prognosis of Colon Cancer

Yue¹,

Wu²,

Qi³

et al. 2021

JIR

View full text Add to dashboard Cite

Purpose The inflammatory response plays a crucial role in the occurrence and development of colon cancer. In this study, we aimed to explore a novel prognostic model for patients with colon cancer (COAD) based on inflammatory response-related genes. Methods Inflammatory response-related genes were obtained from Molecular Signatures database. Univariate and multivariate Cox regression analyses were used for model construction based on TCGA dataset. GSE39582 dataset and qRT-PCR dataset were used for validation. Gene set variation analysis and gene set enrichment analysis were performed to explore the potential regulatory pathways. The immune cell infiltration level was analyzed via CIBERSORT. Immunohistochemistry analysis and experiments were used to explore the function of genes in model. Results In this study, a novel prognostic signature was identified using stepwise Cox proportional hazards regression analysis based on TCGA dataset. The results were subsequently validated in 562 patients from GSE39582 and a qRT-PCR data set from 70 tumor samples. Functional analysis indicated that the tumor microenvironment and immune cell infiltrate were different between high- and low-risk groups. Additionally, IHC results showed that the protein levels of prognostic genes were significantly different between COAD tissues and adjacent non-tumorous tissues, and prognostic genes could regulate the malignant phenotype of COAD cells. Conclusion Overall, the inflammation-related gene signature can be used for prognostic prediction in patients with COAD.

show abstract

Identification of key genes unique to the luminal a and basal-like breast cancer subtypes via bioinformatic analysis

Cited by 23 publications

References 37 publications

Expression levels and clinical values of miR-92b-3p in breast cancer

Expression levels and clinical values of miR-92b-3p in breast cancer

Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer

Identification and Validation of a Novel Inflammatory Response-Related Gene Signature for the Prognosis of Colon Cancer

Contact Info

Product

Resources

About